ExploreWatchlistsPricing
  1. JP-listed companies
  2. Human Metabolome Technologies, Inc.
  3. Financials
  4. Return on equity (%)

Human Metabolome Technologies, Inc. (6090)

Market cap
¥3.7B
P/E ratio
17.3x
Provides high-sensitivity analysis of metabolic compounds to pharmaceutical companies, research institutions, and manufacturers to support drug development and product testing.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on equity (%) (Million JPY)YoY (%)
Jun 30, 202513.3+1.68%
Jun 30, 202413.1-25.43%
Jun 30, 202317.5-10.05%
Jun 30, 202219.5+314.89%
Jun 30, 20214.7-230.56%
Jun 30, 2020-3.6-91.04%
Jun 30, 2019-40.2+77.98%
Mar 31, 2019-22.6+160.32%
Mar 31, 2018-8.7+136.89%
Mar 31, 2017-3.7-20.43%
Mar 31, 2016-4.6+107.21%
Mar 31, 2015-2.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat